ReachMD CME

CME credits: 1.00 Valid until: 20-10-2027 Claim your CME credit at https://reachmd.com/cme/nephrology/the-binder-selection-playbook-matching-the-right-strategy-to-the-right-patient/70431/ This MinuteCE series examines practical approaches to hyperkalemia management in patients with chronic kidney disease (CKD), heart failure, diabetes, and other cardiorenal comorbidities. Through expert lectures,...

CME credits: 1.00 Valid until: 20-10-2027 Claim your CME credit at https://reachmd.com/cme/nephrology/from-lab-alert-to-action-plan-monitoring-potassium-without-undermining-cardiorenal-protection/70430/ This MinuteCE series examines practical approaches to hyperkalemia management in patients with chronic kidney disease (CKD), heart failure, diabetes, and other cardiorenal comorbidities. Through ex...

CME credits: 1.00 Valid until: 20-10-2027 Claim your CME credit at https://reachmd.com/cme/nephrology/ckd-diabetes-and-albuminuria-keeping-kidney-protective-therapy-on-board-despite-hyperkalemia/70429/ This MinuteCE series examines practical approaches to hyperkalemia management in patients with chronic kidney disease (CKD), heart failure, diabetes, and other cardiorenal comorbidities. Through exp...

CME credits: 1.00 Valid until: 20-10-2027 Claim your CME credit at https://reachmd.com/cme/nephrology/potassium-binders-to-optimize-gdmt-therapy-in-hfref/70428/ This MinuteCE series examines practical approaches to hyperkalemia management in patients with chronic kidney disease (CKD), heart failure, diabetes, and other cardiorenal comorbidities. Through expert lectures, interviews, and case-based...

CME credits: 1.00 Valid until: 20-10-2027 Claim your CME credit at https://reachmd.com/cme/nephrology/the-edema-question-selecting-a-potassium-binder-in-patients-with-hf-or-congestion/70427/ This MinuteCE series examines practical approaches to hyperkalemia management in patients with chronic kidney disease (CKD), heart failure, diabetes, and other cardiorenal comorbidities. Through expert lecture...

CME credits: 1.00 Valid until: 20-10-2027 Claim your CME credit at https://reachmd.com/cme/nephrology/differentiating-oral-potassium-binders-mechanism-onset-and-sodium-load/70426/ This MinuteCE series examines practical approaches to hyperkalemia management in patients with chronic kidney disease (CKD), heart failure, diabetes, and other cardiorenal comorbidities. Through expert lectures, intervie...

CME credits: 1.00 Valid until: 20-10-2027 Claim your CME credit at https://reachmd.com/cme/nephrology/hyperkalemia-as-a-barrier-to-gdmt-why-stopping-gdmt-is-often-the-wrong-reflex/70425/ This MinuteCE series examines practical approaches to hyperkalemia management in patients with chronic kidney disease (CKD), heart failure, diabetes, and other cardiorenal comorbidities. Through expert lectures, i...

CME credits: 1.00 Valid until: 20-10-2027 Claim your CME credit at https://reachmd.com/cme/nephrology/personalized-treatment-strategies-for-hyperkalemia-bridging-evidence-and-clinical-practice-needs/48888/ This MinuteCE series examines practical approaches to hyperkalemia management in patients with chronic kidney disease (CKD), heart failure, diabetes, and other cardiorenal comorbidities. Through...

CME credits: 1.00 Valid until: 31-08-2027 Claim your CME credit at https://reachmd.com/programs/cme/the-future-of-igan-care/67098/ This comprehensive educational activity focuses on 4 key dimensions of IgA nephropathy (IgAN) management. First, attendees will compare and contrast the mechanisms of action (MOAs) of both approved and investigational IgAN therapies, critically evaluating how each targ...

CME credits: 1.00 Valid until: 31-08-2027 Claim your CME credit at https://reachmd.com/programs/cme/the-evolving-role-of-biomarkers-in-igan/67097/ This comprehensive educational activity focuses on 4 key dimensions of IgA nephropathy (IgAN) management. First, attendees will compare and contrast the mechanisms of action (MOAs) of both approved and investigational IgAN therapies, critically evaluati...

CME credits: 1.00 Valid until: 31-08-2027 Claim your CME credit at https://reachmd.com/programs/cme/translating-evidence-into-igan-care/67096/ This comprehensive educational activity focuses on 4 key dimensions of IgA nephropathy (IgAN) management. First, attendees will compare and contrast the mechanisms of action (MOAs) of both approved and investigational IgAN therapies, critically evaluating h...

CME credits: 1.00 Valid until: 31-08-2027 Claim your CME credit at https://reachmd.com/programs/cme/mechanisms-matter-optimizing-proteinuria-reduction-in-igan/67095/ This comprehensive educational activity focuses on 4 key dimensions of IgA nephropathy (IgAN) management. First, attendees will compare and contrast the mechanisms of action (MOAs) of both approved and investigational IgAN therapies,...

CME credits: 1.00 Valid until: 31-08-2027 Claim your CME credit at https://reachmd.com/programs/cme/navigating-kdigo-guidance-in-igan/67094/ This comprehensive educational activity focuses on 4 key dimensions of IgA nephropathy (IgAN) management. First, attendees will compare and contrast the mechanisms of action (MOAs) of both approved and investigational IgAN therapies, critically evaluating how...

CME credits: 1.00 Valid until: 31-08-2027 Claim your CME credit at https://reachmd.com/programs/cme/proteinuria-in-igan-the-signal-the-target-and-the-treatment-goal/67093/ This comprehensive educational activity focuses on 4 key dimensions of IgA nephropathy (IgAN) management. First, attendees will compare and contrast the mechanisms of action (MOAs) of both approved and investigational IgAN thera...

CME credits: 1.00 Valid until: 31-08-2027 Claim your CME credit at https://reachmd.com/programs/cme/unmasking-igan-achieving-earlier-diagnosis/67092/ This comprehensive educational activity focuses on 4 key dimensions of IgA nephropathy (IgAN) management. First, attendees will compare and contrast the mechanisms of action (MOAs) of both approved and investigational IgAN therapies, critically evalu...

CME credits: 1.00 Valid until: 31-08-2027 Claim your CME credit at https://reachmd.com/programs/cme/the-hidden-danger-of-igan-pathogenesis-and-unmet-needs/48884/ This comprehensive educational activity focuses on 4 key dimensions of IgA nephropathy (IgAN) management. First, attendees will compare and contrast the mechanisms of action (MOAs) of both approved and investigational IgAN therapies, crit...

CME credits: 0.50 Valid until: 27-08-2027 Claim your CME credit at https://reachmd.com/programs/cme/translating-safety-data-into-practice-effective-ae-management-in-oral-serd-and-protac-regimens/67125/ Hear an expert discussion between Dr. Komal Jhaveri and Dr. Virginia Kaklamani as they examine the evolving role of oral selective estrogen receptor degraders (SERDs), including PROTACs and novel co...

CME credits: 0.50 Valid until: 27-08-2027 Claim your CME credit at https://reachmd.com/programs/cme/the-sequencing-puzzle-integrating-oral-serds-and-protacs-into-the-mbc-treatment-landscape/67124/ Hear an expert discussion between Dr. Komal Jhaveri and Dr. Virginia Kaklamani as they examine the evolving role of oral selective estrogen receptor degraders (SERDs), including PROTACs and novel combina...

CME credits: 0.50 Valid until: 27-08-2027 Claim your CME credit at https://reachmd.com/programs/cme/navigating-treatment-selection-after-first-line-cdk46-inhibitor-progression/67123/ Hear an expert discussion between Dr. Komal Jhaveri and Dr. Virginia Kaklamani as they examine the evolving role of oral selective estrogen receptor degraders (SERDs), including PROTACs and novel combination strategie...

CME credits: 0.50 Valid until: 27-08-2027 Claim your CME credit at https://reachmd.com/programs/cme/redefining-endocrine-therapy-the-evidence-behind-oral-serds-and-protac-er-degraders/67122/ Hear an expert discussion between Dr. Komal Jhaveri and Dr. Virginia Kaklamani as they examine the evolving role of oral selective estrogen receptor degraders (SERDs), including PROTACs and novel combination s...

CME credits: 0.25 Valid until: 26-08-2027 Claim your CME credit at https://reachmd.com/programs/cme/engaging-patients-with-heart-failure-and-chronic-hyperkalemia-shared-decision-making-to-support-guideline-directed-medical-therapy/37616/ In this Patient-Clinician Connection, Dr. Gianluigi Savarese uses a clinical case to demonstrate shared decision-making strategies for managing chronic and recurr...

CME credits: 0.75 Valid until: 24-08-2027 Claim your CME credit at https://reachmd.com/programs/cme/case-consult-implementing-anti-cd38based-frontline-regimens-in-transplant-ineligible-patients/67248/ This online educational activity reviews the clinical evidence supporting anti-CD38 monoclonal antibody–based combinations as foundational frontline therapy for patients with newly diagnosed multiple...

CME credits: 0.75 Valid until: 24-08-2027 Claim your CME credit at https://reachmd.com/programs/cme/clinical-evidence-for-anti-cd38based-frontline-regimens-in-transplant-ineligible-patients-with-multiple-myeloma/60962/ This online educational activity reviews the clinical evidence supporting anti-CD38 monoclonal antibody–based combinations as foundational frontline therapy for patients with newly...

CME credits: 0.75 Valid until: 24-08-2027 Claim your CME credit at https://reachmd.com/programs/cme/case-consult-implementing-anti-cd38based-frontline-regimens-in-transplant-eligible-patients/60961/ This online educational activity reviews the clinical evidence supporting anti-CD38 monoclonal antibody–based combinations as foundational frontline therapy for patients with newly diagnosed multiple m...

CME credits: 0.75 Valid until: 24-08-2027 Claim your CME credit at https://reachmd.com/programs/cme/clinical-evidence-for-anti-cd38based-frontline-regimens-in-transplant-eligible-patients-with-multiple-myeloma/60960/ This online educational activity reviews the clinical evidence supporting anti-CD38 monoclonal antibody–based combinations as foundational frontline therapy for patients with newly di...